Robertson D M, Cahir N, Burger H G, Mamers P, Groome N
Prince Henry's Institute of Medical Research, Clayton, Victoria, Australia.
Clin Endocrinol (Oxf). 1999 Mar;50(3):381-6. doi: 10.1046/j.1365-2265.1999.00656.x.
Previous studies have shown that serum inhibin as measured by alpha subunit-directed radioimmunoassay (RIA) and inhibin A ELISA was elevated in postmenopausal women with mucinous and granulosa cell cancers, with the RIA showing a more frequent elevation than the inhibin A ELISA. It was thus hypothesised that these cancers may also produce inhibin B or the free alpha subunit. The aim of the study was to identify the forms of inhibin found in a range of ovarian cancers using a range of inhibin assays with varying specificities.
Serum samples obtained from women with ovarian cancer were assayed by inhibin B ELISA and Pro-alpha C subunit ELISA and compared with inhibin RIA and inhibin A ELISA.
Blood samples were obtained from 34 postmenopausal women (> 55 years) with no history of endocrine disease and from women with ovarian serous cystadenocarcinomas (n = 66), mucinous cystadenocarcinomas (n = 20), granulosa cell tumours (n = 9-11), miscellaneous ovarian cancers (n = 46) and non ovarian cancers (n = 23).
Inhibin B and inhibin Pro-alpha C subunit levels were determined by ELISA and compared to values obtained by RIA and inhibin A ELISA. Cancers were discriminated from controls based on values obtained 2SD above the geometric mean of the control values.
Granulosa cell tumours were detected by RIA and inhibin B ELISA (100%), Pro-alpha C ELISA (90%) and inhibin A ELISA (77%). Mucinous tumours were detected by RIA (70%), inhibin B ELISA (60%), Pro-alpha C ELISA (55%) and inhibin A (20%). Serous tumours were detected by RIA (35%) and the other assays (< 15%). Miscellaneous tumours were detected by RIA (41%) and other assays < 30%.
Ovarian neoplasms may produce a variety of peptides related to the inhibins, including dimeric inhibin A and B. Inhibin B is detected in more ovarian cancers than inhibin A but does not discriminate as well as the alpha subunit directed assays. The higher discrimination index obtained with the RIA compared to the Pro-alpha C ELISA suggests that assays detecting all inhibin forms containing the alpha subunit and not just those detecting the Pro-alpha C subunit will provide the most useful detection method.
既往研究表明,采用α亚基定向放射免疫测定法(RIA)和抑制素A酶联免疫吸附测定法(ELISA)检测时,黏液性癌和颗粒细胞瘤绝经后女性的血清抑制素水平升高,其中RIA显示升高更为常见。因此推测,这些癌症可能也会产生抑制素B或游离α亚基。本研究的目的是使用一系列特异性不同的抑制素测定法,确定一系列卵巢癌中发现的抑制素形式。
采用抑制素B ELISA和前αC亚基ELISA对卵巢癌女性的血清样本进行检测,并与抑制素RIA和抑制素A ELISA进行比较。
采集了34名无内分泌疾病史的绝经后女性(>55岁)以及患有卵巢浆液性囊腺癌(n = 66)、黏液性囊腺癌(n = 20)、颗粒细胞瘤(n = 9 - 11)、其他类型卵巢癌(n = 46)和非卵巢癌(n = 23)的女性的血样。
通过ELISA测定抑制素B和抑制素前αC亚基水平,并与RIA和抑制素A ELISA获得的值进行比较。根据高于对照值几何平均值2个标准差所获得的值,将癌症与对照区分开来。
颗粒细胞瘤通过RIA、抑制素B ELISA(100%)、前αC ELISA(90%)和抑制素A ELISA(77%)检测到。黏液性肿瘤通过RIA(70%)、抑制素B ELISA(60%)、前αC ELISA(55%)和抑制素A(20%)检测到。浆液性肿瘤通过RIA(35%)和其他检测方法(<15%)检测到。其他类型肿瘤通过RIA(41%)和其他检测方法(<30%)检测到。
卵巢肿瘤可能产生多种与抑制素相关的肽,包括二聚体抑制素A和B。与抑制素A相比,更多的卵巢癌中检测到抑制素B,但与α亚基定向检测方法相比,其鉴别能力欠佳。与前αC ELISA相比,RIA获得的鉴别指数更高,这表明检测所有含α亚基的抑制素形式而不仅仅是检测前αC亚基的检测方法将提供最有用的检测方法。